Skip to main content
main-content

08-06-2020 | ASCO 2020 | Conference coverage | Video

Expert highlights: Targeting HER2 and EGFR in NSCLC

Tejas Patil gives his non-small-cell lung cancer highlights for patients positive for HER2 or EGFR mutations including the DESTINY-Lung01 and ECOG-ACRIN 5162 studies (10:29).

Read transcript

Enriched treatment pathway for non-driver NSCLC

What is it and why do I need it?

Have your say on Medicine Matters

Visit the conference hub

Image Credits